BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. Founded by Carolyn Short, Jay M. Short, and Jay Short in 2007, BioAtla is backed by investors that include Janus Henderson Investors, Cormorant Asset Management, Pfizer Venture Investments, HBM Healthcare Investments AG, and Farallon Capital Management and is headquartered in San Diego.